Sugi Predict

Sugi Predict / Compounds / SCHEMBL136664

SCHEMBL136664

SCHEMBL136664

O=c1cc(OCc2ccccc2)cc[nH]1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ NSD2 O96028 1/20 1.00
▸ ABL1 P00519 1/20 1.00
▸ PPARG P37231 1/20 1.00
▸ RIN1 Q13671 1/20 1.00
▸ L3MBTL1 Q9Y468 1/20 1.00
▸ NCOR2 Q9Y618 1/20 1.00
▸ IP6K1 Q92551 1/20 0.55
▸ MAOB P27338 10/20 0.54
▸ MAOA P21397 6/20 0.54
▸ ALOX5 P09917 1/20 0.51
▸ TOP1 P11387 1/20 0.51
▸ GSTP1 P09211 1/20 0.50
▸ POLB P06746 1/20 0.50
▸ CTSV O60911 1/20 0.49
▸ CTSL P07711 1/20 0.49
▸ MAPK14 Q16539 1/20 0.49
▸ NR4A2 P43354 1/20 0.49
▸ DPYD Q12882 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27904706 0.94 NSD2 (0.88) NSD2ABL1PPARGRIN1L3MBTL1
SCHEMBL26006638 0.84 NSD2 (0.71) NSD2ABL1PPARGRIN1L3MBTL1
SCHEMBL1003510 0.83 NSD2 (0.71) NSD2ABL1PPARGRIN1L3MBTL1
SCHEMBL15889565 0.83 NSD2 (0.71) NSD2ABL1PPARGRIN1L3MBTL1
SCHEMBL1003502 0.83 NSD2 (0.71) NSD2ABL1PPARGRIN1L3MBTL1
SCHEMBL12949746 0.83 NSD2 (0.71) NSD2ABL1PPARGRIN1L3MBTL1
SCHEMBL15111341 0.83 NSD2 (0.70) NSD2ABL1PPARGRIN1L3MBTL1
SCHEMBL1753704 0.83 NSD2 (0.71) NSD2ABL1PPARGRIN1L3MBTL1
SCHEMBL119148 0.82 NSD2 (0.69) NSD2ABL1PPARGRIN1L3MBTL1
SCHEMBL4232057 0.82 NSD2 (0.68) NSD2ABL1PPARGRIN1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 514 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220031607-A1 INJECTION COMPOSITION CONTAINING FAB I INHIBITOR, AND PREPARATION METHOD THEREFOR CRYSTALGENOMICS, INC. (KR) 2022-02-03 — — US claimed
US-20220016098-A1 ORALLY ADMINISTERED PHARMACEUTICAL COMPOSITION COMPRISING FAB I INHIBITORS AND METHOD FOR PREPARING SAME CRYSTALGENOMICS, INC. (KR) 2022-01-20 — — US claimed
EP-3915538-A1 INJECTION COMPOSITION CONTAINING FAB I INHIBITOR, AND PREPARATION METHOD THEREFOR Crystalgenomics, Inc. (KR) 2021-12-01 — — EP claimed
CN-113613627-A Injection composition containing Fab I inhibitor and preparation method thereof 晶体基因技术株式会社 2021-11-05 — — CN claimed
EP-3824888-A1 ORALLY ADMINISTERED PHARMACEUTICAL COMPOSITION COMPRISING FAB I INHIBITORS AND METHOD FOR PREPARING SAME Crystalgenomics, Inc. (KR) 2021-05-26 — — EP claimed
CN-112423751-A Orally administered pharmaceutical compositions comprising Fab I inhibitors and methods of making the same 晶体基因技术株式会社 2021-02-26 — — CN claimed
WO-2020017756-A1 ORALLY ADMINISTERED PHARMACEUTICAL COMPOSITION COMPRISING FAB I INHIBITORS AND METHOD FOR PREPARING SAME 크리스탈지노믹스(주) 2020-01-23 — — WO claimed
CN-102060758-B Preparation method of 4-benzyloxy-pyridine-2-ketone UNIV HANGZHOU NORMAL 2012-12-05 — — CN claimed
CN-102060758-A Preparation method of 4-benzyloxy-pyridine-2-ketone UNIV HANGZHOU NORMAL 2011-05-18 — — CN claimed
CN-1646125-A Substituted pyridones as modulators of P38MAP kinase PHARMACIA CORP (US) 2005-07-27 — — CN claimed
EP-1490064-A1 SUBSTITUTED PYRIDINONES AS MODULATORS OF P38 MAP KINASE Pharmacia Corporation (US) 2004-12-29 — — EP claimed
US-20040058964-A1 Substituted pyridinones PHARMACIA LLC 2004-03-25 — — US claimed
WO-2003068230-A1 SUBSTITUTED PYRIDINONES AS MODULATORS OF P38 MAP KINASE PHARMACIA CORPORATION (US) 2003-08-21 — — WO claimed
EP-3911640-B1 PCSK9 INHIBITORS FOR USE IN THERAPY, ESPECIALLY THE TREATMENT OF CARDIOVASCULAR DISEASE ASTRAZENECA AB (SE) 2026-05-13 — — EP disclosed
US-12584120-B2 PCSK9 inhibitors and methods of use thereof ASTRAZENECA AB (SE) 2026-03-24 — — US disclosed
US-12552807-B2 PCSK9 inhibitors and methods of use thereof ASTRAZENECA AB (SE) 2026-02-17 — — US disclosed
WO-1997030992-A1 INHIBITORS OF FARNESYL PROTEIN TRANSFERASE BRISTOL-MYERS SQUIBB COMPANY (US) 1997-08-28 — — WO disclosed
WO-1997009311-A1 NEW 4-(OXYALKOXYPHENYL)-3-OXY-PIPERIDINES FOR TREATING HEART AND KIDNEY INSUFFICIENCY F. HOFFMANN-LA ROCHE AG (CH) 1997-03-13 — — WO disclosed
US-5484761-A PRE OR POSTEMERGENT HERBICIDES MONSANTO COMPANY (US) 1996-01-16 — — US disclosed
US-3853900-A 4-BENZYLOXY-2 (1H)-PYRIDONES SEARLE & CO 1974-12-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220016098-A1 ORALLY ADMINISTERED PHARMACEUTICAL COMPOSITION COMPRISING FAB I INHIBITORS AND METHOD FOR PREPARING SAME FCGRT, PEF1, SI NSD2 3609/4885ABL1 497/4885PPARG 4428/4885
US-12552807-B2 PCSK9 inhibitors and methods of use thereof PCSK9, PCSK7, PCSK6 NSD2 2239/4885ABL1 767/4885PPARG 1886/4885
US-20040058964-A1 Substituted pyridinones MAPK1, MAPK6, MAPK7 NSD2 4745/4885ABL1 614/4885PPARG 1624/4885
US-12584120-B2 PCSK9 inhibitors and methods of use thereof PCSK9, LDLR, PCSK7 NSD2 2052/4885ABL1 171/4885PPARG 3501/4885
US-20220031607-A1 INJECTION COMPOSITION CONTAINING FAB I INHIBITOR, AND PREPARATION METHOD THEREFOR FAR1, NOTUM, IDE NSD2 4503/4885ABL1 1429/4885PPARG 4096/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.